LENUS Collection:

New targeted therapies for NSCLC.

Sat, 01 Jan 2011 00:00:00 GMT

Title: New targeted therapies for NSCLC. Authors: Carney, D

The effect of short term neo-adjuvant androgen deprivation on erectile function in patients treated with external beam radiotherapy for localised prostate cancer: an analysis of the 4- versus 8-month randomised trial (Irish Clinical Oncology Research Group 97-01).

Sun, 01 Jul 2012 00:00:00 GMT

Title: The effect of short term neo-adjuvant androgen deprivation on erectile function in patients treated with external beam radiotherapy for localised prostate cancer: an analysis of the 4- versus 8-month randomised trial (Irish Clinical Oncology Research Group 97-01). Authors: Daly, Patricia E; Dunne, Mary T; O'Shea, Carmel M; Finn, Marie A; Armstrong, John G Abstract: Erectile dysfunction is a common consequence of external beam radiotherapy (EBRT) for prostate cancer. The addition of neo-adjuvant androgen deprivation (NAD) has an indeterminate additive effect. We examined the long-term effect on erectile function (EF) of two durations (4 months: arm 1 and 8 months: arm 2) of NAD prior to radiation (RT) for patients with localised prostate cancer from the Irish Clinical Oncology Research Group (ICORG 97-01) 4- versus 8-month trial. In this study we aimed to (1) analyse the overall effect on EF of NAD in an EBRT population, (2) compare the probability of retained EF over time in an EBRT population treated with either 4 or 8 months of NAD and (3) identify any variables such as risk group and age which may have an additive detrimental effect. This analysis provides unique long term follow up data.

Perforation of colon cancer into a benign ovarian cyst.

Sun, 01 Apr 2012 00:00:00 GMT

Title: Perforation of colon cancer into a benign ovarian cyst. Authors: Walsh, S; Evoy, D; Cantwell, C P; Kroon, N; Sheahan, K; Gibbons, D; McDermott, E W

mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors.

Sun, 01 Apr 2012 00:00:00 GMT

Title: mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors. Authors: Walsh, S; Flanagan, L; Quinn, C; Evoy, D; McDermott, E W; Pierce, A; Duffy, M J Abstract: Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptors (ER), progesterone receptors (PR) and overexpression of HER2. Targeted therapy is currently unavailable for this subgroup of breast cancer patients. mTOR controls cancer cell growth, survival and invasion and is thus a potential target for the treatment of patients with TNBC. Using immunohistochemistry, mTOR and p-mTOR were measured in 89 TNBCs and 99 non-TNBCs. While mTOR expression was confined to tumor cell cytoplasm, p-mTOR staining was located in the nucleus, perinuclear area and in the cytoplasm. Potentially important, was our finding that nuclear p-mTOR was found more frequently in triple-negative than non triple-negative cancers (p < 0.001). These results suggest that mTOR may play a more important role in the progression of TNBC compared to non-TNBC. Based on these findings, we conclude that mTOR may be a new target for the treatment of triple-negative breast cancer.